3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
56
Leukemia
52
Lymphoma
37
Myelodysplastic Syndromes
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Lymphoma, Non-Hodgkin
22
Hodgkin Disease
22
Leukemia, Myeloid, Acute
18
Multiple Myeloma
17
Myeloproliferative Disorders
14
Recurrence
12
Lymphoma, Mantle-Cell
12
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, T-Cell, Peripheral
10
Lymphoma, Follicular
10
Congenital Abnormalities
10
Neoplasms, Plasma Cell
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Chronic-Phase
9
Hematologic Neoplasms
9
Burkitt Lymphoma
9
Anemia, Aplastic
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Waldenstrom Macroglobulinemia
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, T-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Graft vs Host Disease
7
Sezary Syndrome
6
Primary Myelofibrosis
6
Interventions
Mitomycin
3
Surveys and Questionnaires
2
Hyperthermic Intraperitoneal Chemotherapy
2
Capecitabine
2
Bromelains
2
Acetylcysteine
2
tislelizumab
1
molgramostim
1
irinotecan sucrosofate
1
cryoprecipitate coagulum
1
Tacrolimus
1
Standard of Care
1
Specimen Handling
1
Sirolimus
1
Referral and Consultation
1
Radiosurgery
1
Psychiatric Rehabilitation
1
Pharmacogenomic Testing
1
Oxaliplatin
1
Nivolumab
1
Methods
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Lansoprazole
1
Ipilimumab
1
Gemcitabine
1
Fluorouracil
1
Floxuridine
1
Early Intervention, Educational
1
Cytoreduction Surgical Procedures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pseudomyxoma Peritonei
×
Alemtuzumab
×
Clear all
NCT06084780
2026-04-09
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled